Japan Artificial Intelligence In Drug Discovery Market Size & Outlook
- Healthcare IT
- AI in Healthcare
- Artificial Intelligence in Drug Discovery Market Outlook
- AI in Healthcare
Global Market
Related Markets
Ask Prism AI about the artificial intelligence in drug discovery market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Japan artificial intelligence in drug discovery market highlights
- The Japan artificial intelligence in drug discovery market generated a revenue of USD 83.8 million in 2025 and is expected to reach USD 609.6 million by 2033.
- The Japan market is expected to grow at a CAGR of 28.2% from 2026 to 2033.
- In terms of segment, neurodegenerative diseases was the largest revenue generating therapeutic space in 2025.
Artificial intelligence in drug discovery market data book summary
| Market revenue in 2025 | USD 83.8 million |
| Market revenue in 2033 | USD 609.6 million |
| Growth rate | 28.2% (CAGR from 2026 to 2033) |
| Largest segment | Neurodegenerative diseases |
| Fastest growing segment | Other |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Other |
| Key market players worldwide | International Business Machines Corp, Exscientia PLC ADR, Insilico Medicine, Aitia, Alphabet Inc Class A, Benevolent AI, BioSymetrics, Atomwise, Insitro, Recursion Pharmaceuticals Inc Class A |
Other key industry trends
- In terms of revenue, Japan accounted for 3.6% of the global artificial intelligence in drug discovery market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China artificial intelligence in drug discovery market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 558.4 million by 2033.
Increasing adoption of AI in drug discovery in the country for shortening the time for discovering drug candidates by eliminating advanced compounds that can cause adverse side effects is contributing to market growth.
In addition, increasing collaborations for discovering and developing new drugs more efficiently is expected to boost the market over the coming years. For instance, in October 2020, Insilico Medicine announced its collaboration with Taisho Pharmaceutical Co., Ltd. for identifying novel therapeutics against aging through AI.
In December 2018, the Japanese government initiated steps to revamp the country’s healthcare system. For instance, Jisedai Iryo-kiban Ho, a next-generation medical infrastructure law, supports anonymous application of medical big data for research related to disease and drug development.
No credit card required*
Publish Date: Apr 21, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Artificial Intelligence In Drug Discovery Market Scope
Artificial Intelligence In Drug Discovery Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| International Business Machines Corp | View profile | 282,200 | One New Orchard Road, Armonk, NY, United States, 10504 | www.ibm.com |
| Alphabet Inc Class A | View profile | 180,895 | 1600 Amphitheatre Parkway, Mountain View, CA, United States, 94043 | www.abc.xyz |
| Exscientia PLC ADR | View profile | 483 | Oxford Science Park, The Schrodinger Building, Oxford, United Kingdom, OX4 4GE | www.exscientia.ai |
| Insilico Medicine | View profile | 101-250 | Hong Kong, Hong Kong Island, Hong Kong, Asia | www.insilico.com |
| Aitia | View profile | 51-100 | Somerville, Massachusetts, United States, North America | www.aitiabio.com/ |
| Benevolent AI | View profile | 248 | 4-8 Maple Street, London, United Kingdom, W1T 5HD | www.benevolent.com |
| Recursion Pharmaceuticals Inc Class A | View profile | 500 | 41 S Rio Grande Street, Salt Lake City,, UT, United States, 84101 | www.recursion.com |
| BioSymetrics | View profile | 11-50 | New York, New York, United States, North America | www.biosymetrics.com |
| Atomwise | View profile | 51-100 | San Francisco, California, United States, North America | www.atomwise.com |
| Insitro | View profile | 101-250 | South San Francisco, California, United States, North America | www.insitro.com |
Japan Artificial Intelligence in Drug Discovery Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Artificial Intelligence in Drug Discovery Market Outlook will help companies and investors design strategic landscapes.
Neurodegenerative Diseases was the largest segment with a revenue share of 27.8% in 2025.
Horizon Databook has segmented the Japan artificial intelligence in drug discovery market based on oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious disease, other covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing adoption of AI in drug discovery in the country for shortening the time for discovering drug candidates by eliminating advanced compounds that can cause adverse side effects is contributing to market growth.
In addition, increasing collaborations for discovering and developing new drugs more efficiently is expected to boost the market over the coming years. For instance, in October 2020, Insilico Medicine announced its collaboration with Taisho Pharmaceutical Co., Ltd. for identifying novel therapeutics against aging through AI.
In December 2018, the Japanese government initiated steps to revamp the country’s healthcare system. For instance, Jisedai Iryo-kiban Ho, a next-generation medical infrastructure law, supports anonymous application of medical big data for research related to disease and drug development.
- Japan Artificial Intelligence In Drug Discovery Market Therapeutic Space Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Disease
- Metabolic Diseases
- Infectious Disease
- Other
- Japan Artificial Intelligence In Drug Discovery Market Application Outlook (Revenue, USD Million , 2021-2033)
- Drug optimisation and repurposing
- Preclinical testing
- Others
Reasons to subscribe to Artificial Intelligence in Drug Discovery Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Artificial Intelligence in Drug Discovery Market Outlook databook
- Our clientele includes a mix of Artificial Intelligence in Drug Discovery Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Artificial Intelligence in Drug Discovery Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Artificial Intelligence in Drug Discovery Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Artificial Intelligence In Drug Discovery Market, 2021-2033 (US$M)
Japan artificial intelligence in drug discovery market statistics, by therapeutic space, 2021-2033 (US$M)
